Evolution of Oricula


Oricula Therapeutics evolved from converging research into hearing loss and compounds that have potential to prevent it. Results of this research identified compounds that protect these cells from ototoxins, specifically aminoglycoside antibiotics known to damage these cells. This research and its resulting patents created the foundation for Oricula Therapeutics.

Key company and product milestones:

  • Novel screening method using zebrafish developed at University of Washington

  • Research using the aminoglycosides class of antibiotics (AGs) as ototoxins leads to identification of a compound that protects hair cells in zebrafish, ORC-0001

  • Auditory Brainstem Response in rats demonstrates mammalian efficacy of ORC-0001

  • Method of Use Patent awarded to University of Washington for protectant compound ORC-0001

  • NINDS Blueprint Neurotherapeutics Program (NIH BPN) Research Grant awarded

  • Drug discovery and pharmeceutical industry expertise added to team

  • Structured Activity Relationship (SAR) and ADME research identifies five analogs to ORC-0001 that are order-of-magnitude more potent, effective, and possess excellent pharmacokinetics and safety profiles

  • Composition of Matter Patent for ORC-0001 analogs applied for by University of Washington

  • Oricula Therapeutics LLC founded

  • Patents for Method of Use and Composition of Matter exclusively licensed from University of Washington by Oricula Therapeutics

  • Washington State Life Sciences Development Fund awards University of Washington grant to fund mammalian efficacy testing of BPN analogs

  • Oricula Therapeutics awarded a Phase 1 SBIR by NIH NIDCD to study safety of ORC-13661

  • Oricula Therapeutics awarded a Phase 2 SBIR by NIH NIAID to advance ORC-13661 to FDA-IND